Trial Profile
Long Term Subcutaneous Tinzaparin [tinzaparin sodium] Compared With Tinzaparin and Oral Anticoagulants [acenocoumarol] in the Treatment of the Acute Pulmonary Embolism.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Tinzaparin sodium (Primary) ; Acenocoumarol
- Indications Pulmonary embolism
- Focus Adverse reactions
- 12 Feb 2009 Actual patient numbers (102) added as reported by ClinicalTrials.gov.
- 12 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jul 2008 New trial record.